Loading provider…
Loading provider…
Gastroenterology Physician in Miami, FL
NPI: 1205815529Primary Practice Location
Baptist Health Endoscopy Center at Galloway North
7500 Southwest 87th Avenue, Miami, FL
Primary Employer
Miami Gastroenterology Consultants, PA
miamigastroenterology.com
HQ Phone
Get MD Miguel's Phone Numberphone_androidMobile
Get MD Miguel's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
FL State Medical License
1995 - 2027

American Board of Internal Medicine
Gastroenterology
Rutgers Health/New Jersey Medical School
Fellowship • Transplant Hepatology
1993 - 1994
University of Connecticut
Fellowship • Gastroenterology
1990 - 1992
Harlem Hospital Center
Residency • Internal Medicine
1985 - 1988
Residency • Internal Medicine
1989 - 1990
Universidad Nacional Pedro Henriquez Urena
Medical School • Pre-Medicine Studies
1975 - 1978
Medical School
Until 1983
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 125 | 208 |
| 2 | 99204New patient office or other outpatient visit, 45-59 minutes | 92 | 92 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 79 | 98 |
| 4 | 99223Initial hospital inpatient care, typically 70 minutes per day | 77 | 95 |
| 5 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 68 | 331 |
Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis
Authors: Cañete, Juan D, Nolla, Joan M, Queiro, Ruben, Rodríguez, Miguel J, Ruiz, Miguel, Lizán, Luis
Journal: J Rheumatol
Publication Date: 2020-02-01
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo SC, DRUG: Mirikizumab SC, DRUG: Mirikizumab IV
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Mirikizumab
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Mirikizumab, DRUG: Ustekinumab